These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 17157662

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis.
    Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, Risma KA, Akers RM, Kirby CL, Buckmeier BK, Assa'ad AH, Hogan SP, Rothenberg ME.
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):22-31. PubMed ID: 17592361
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis.
    Sayej WN, Patel R, Baker RD, Tron E, Baker SS.
    J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):393-9. PubMed ID: 19633574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.
    Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME.
    J Allergy Clin Immunol; 2007 Dec; 120(6):1292-300. PubMed ID: 18073124
    [Abstract] [Full Text] [Related]

  • 10. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.
    Bhattacharya B, Carlsten J, Sabo E, Kethu S, Meitner P, Tavares R, Jakate S, Mangray S, Aswad B, Resnick MB.
    Hum Pathol; 2007 Dec; 38(12):1744-53. PubMed ID: 17900656
    [Abstract] [Full Text] [Related]

  • 11. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.
    Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
    [Abstract] [Full Text] [Related]

  • 12. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
    Dohil R, Newbury R, Fox L, Bastian J, Aceves S.
    Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
    [Abstract] [Full Text] [Related]

  • 13. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis.
    Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE, Putnam PE, Rothenberg ME.
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1328-36. PubMed ID: 17059896
    [Abstract] [Full Text] [Related]

  • 14. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis.
    Gonsalves N, Policarpio-Nicolas M, Zhang Q, Rao MS, Hirano I.
    Gastrointest Endosc; 2006 Sep; 64(3):313-9. PubMed ID: 16923475
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
    Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB, Klion AD.
    J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.